Research programme: sodium ion channel modulators - Purdue Pharma

Drug Profile

Research programme: sodium ion channel modulators - Purdue Pharma

Alternative Names: NaV1.7 ion channel modulators - Purdue Pharma

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Purdue Pharma
  • Developer AnaBios Corporation; Purdue Pharma
  • Class Non-opioid analgesics
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Pain

Most Recent Events

  • 05 Dec 2016 Purdue license the rights to a suite of patents for NaV1.7 sodium ion channel blockers to AnaBios
  • 22 Sep 2015 Purdue Pharma and AnaBios form a joint venture to develop NaV1.7 sodium ion channel compounds for the treatment of chronic pain
  • 22 Sep 2015 Early research in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top